• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一例使用帕博利珠单抗和乐伐替尼作为平滑肌肉瘤替代疗法的病例。

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma.

作者信息

Mehta Naaman, Lee Sarah S, Salame Ghadir

机构信息

Department of Obstetrics and Gynecology, NYU Langone Health, 550 First Avenue, New York, NY 10016, United States.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, NYU Langone Health, 550 First Avenue, New York, NY 10016, United States.

出版信息

Gynecol Oncol Rep. 2023 Jan 27;45:101145. doi: 10.1016/j.gore.2023.101145. eCollection 2023 Feb.

DOI:10.1016/j.gore.2023.101145
PMID:36818196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9932649/
Abstract

•Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse.•Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS.•This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient with recurrent LMS.

摘要

•关于平滑肌肉瘤（LMS）治疗的研究仍然很少。

•派姆单抗/乐伐替尼已被报道可用于治疗子宫内膜癌，但尚未用于治疗LMS。

•本报告显示了一名复发性LMS患者使用派姆单抗和乐伐替尼后疾病出现缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea3/9932649/55e4149f6767/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea3/9932649/ab7c23291884/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea3/9932649/1fb5b8ade997/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea3/9932649/55e4149f6767/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea3/9932649/ab7c23291884/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea3/9932649/1fb5b8ade997/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea3/9932649/55e4149f6767/gr3.jpg

相似文献

1
A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma.一例使用帕博利珠单抗和乐伐替尼作为平滑肌肉瘤替代疗法的病例。
Gynecol Oncol Rep. 2023 Jan 27;45:101145. doi: 10.1016/j.gore.2023.101145. eCollection 2023 Feb.
2
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.帕博利珠单抗联合仑伐替尼对比化疗用于晚期或复发性子宫内膜癌一线治疗的 III 期、随机、开放标签研究：ENGOT-en9/LEAP-001。
Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19.
3
Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.乐伐替尼与帕博利珠单抗联合治疗帕博利珠单抗预处理的复发子宫内膜癌的疗效
Gynecol Oncol Rep. 2022 Oct 12;44:101084. doi: 10.1016/j.gore.2022.101084. eCollection 2022 Dec.
4
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity.帕博利珠单抗联合乐伐替尼治疗晚期子宫内膜癌：病例报告及肺毒性系统评价
Front Oncol. 2023 Jul 10;13:1145986. doi: 10.3389/fonc.2023.1145986. eCollection 2023.
5
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.乐伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者不良反应的特征与管理
Oncologist. 2021 Sep;26(9):e1599-e1608. doi: 10.1002/onco.13883. Epub 2021 Jul 30.
6
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者：一项多中心、开放标签、单臂、2 期临床试验的中期分析。
Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25.
7
Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.子宫平滑肌肉瘤和子宫内膜间质肉瘤具有独特的 miRNA 特征。
Gynecol Oncol. 2016 Mar;140(3):512-7. doi: 10.1016/j.ygyno.2016.01.001. Epub 2016 Jan 6.
8
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.帕博利珠单抗联合推荐起始剂量或降低起始剂量仑伐替尼治疗复发性子宫内膜癌的毒性和疗效。
Gynecol Oncol. 2021 Jul;162(1):24-31. doi: 10.1016/j.ygyno.2021.04.034. Epub 2021 May 3.
9
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌。
N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19.
10
Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.帕博利珠单抗联合仑伐替尼与帕博利珠单抗和仑伐替尼单药治疗癌症的安全性和有效性：系统评价。
Int Immunopharmacol. 2021 Feb;91:107281. doi: 10.1016/j.intimp.2020.107281. Epub 2020 Dec 16.

本文引用的文献

1
What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?治疗平滑肌肉瘤需要进行哪些临床试验？
Curr Treat Options Oncol. 2022 Mar;23(3):439-449. doi: 10.1007/s11864-021-00928-y. Epub 2022 Mar 11.
2
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌。
N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19.
3
Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma.子宫内膜取样术用于子宫平滑肌肉瘤的术前诊断。
J Minim Invasive Gynecol. 2022 Jan;29(1):119-127. doi: 10.1016/j.jmig.2021.07.004. Epub 2021 Jul 13.
4
Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report.仑伐替尼和帕博利珠单抗治疗黏液性苗勒管混合瘤的临床获益：一例报告。
Curr Oncol. 2021 Jun 10;28(3):2146-2149. doi: 10.3390/curroncol28030199.
5
Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature.帕博利珠单抗在微卫星高度不稳定子宫平滑肌肉瘤中的应用；一例病例报告及文献综述。
Gynecol Oncol Rep. 2021 Jan 13;35:100701. doi: 10.1016/j.gore.2021.100701. eCollection 2021 Feb.
6
Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature.高热腹腔内化疗治疗子宫平滑肌肉瘤的手术和肿瘤学结果：文献系统评价。
Gynecol Oncol. 2021 Apr;161(1):70-77. doi: 10.1016/j.ygyno.2020.12.032. Epub 2021 Jan 6.
7
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.一项帕唑帕尼作为不可切除或转移性软组织肉瘤患者一线治疗药物的 II 期研究，这些患者不适于化疗。
Eur J Cancer. 2020 Sep;137:1-9. doi: 10.1016/j.ejca.2020.06.016. Epub 2020 Jul 23.
8
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).吉西他滨联合帕唑帕尼一线治疗后序贯帕唑帕尼维持治疗晚期平滑肌肉瘤的Ⅱ期临床研究（LMS03 研究）：法国癌症肉瘤协作组研究。
Eur J Cancer. 2020 Jan;125:31-37. doi: 10.1016/j.ejca.2019.10.028. Epub 2019 Dec 10.
9
Uterine leiomyosarcoma: A review of the literature and update on management options.子宫平滑肌肉瘤：文献回顾与治疗选择的更新。
Gynecol Oncol. 2018 Dec;151(3):562-572. doi: 10.1016/j.ygyno.2018.09.010. Epub 2018 Sep 21.
10
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.帕博利珠单抗治疗晚期软组织肉瘤和骨肉瘤（SARC028）：一项多中心、双队列、单臂、开放标签的2期试验。
Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4.